Merck plays lion tamer, taking middle dose of ROR ADC forward in relapsed or refractory DLBCL
Merck & Co. has posted phase 2 data on zilovertamab vedotin in lymphoma, providing more evidence of the narrow safety and efficacy window that is open to the ROR1-directed antibody-drug conjugate.
Merck & Co. has posted phase 2 data on zilovertamab vedotin in lymphoma, providing more evidence of the narrow safety and efficacy window that is open to the ROR1-directed antibody-drug conjugate.
